newsfilter
← Latest News
GlobeNewswire·

Cellectis Reports Third Quarter 2026 Financial Results and Provides a Business Update

CLLS
  • .HEAL-101 achieved up to 70% in vivo APOC3 editing with liver-restricted activity & confirmed 76% triglyceride reduction in murine models per ESGCT 2026 data
  • Phase 1 investigator-initiated trial (IIT) for .HEAL-101 in China is on track for initiation with preliminary clinical data expected in H2 2027
  • .HEAL-201 achieved >90% reduction in plasma PCSK9 in a humanized liver mouse model with preliminary clinical data expected in H1 2028
  • Cellectis holds $149 million in cash, cash equivalents & fixed-term deposits as of September 30, 2026, targeting a cash runway into H2 2028
  • Strategic transformation includes discontinuation of lasme-cel & eti-cel programs with global headcount reduction of up to 70% over 2026 & 2027
  • Consolidated revenues & other income fell to $19.9 million for the nine months ended September 30, 2026, down from $67.4 million in the prior period
  • R&D expenses increased to $108.8 million for the nine-month period ended September 30, 2026, primarily driven by $34.9 million in strategic transformation costs
  • Consolidated net loss attributable to shareholders was $101.1 million ($1.00 per share) for the nine months ended September 30, 2026, compared to $41.3 million ($0.41 per share) in 2025
  • Adjusted net loss attributable to shareholders was $95.2 million ($0.95 per share) for the nine months ended September 30, 2026, compared to $37.4 million ($0.37 per share) in 2025
  • AstraZeneca collaboration activities continue under a joint research agreement to develop up to 10 novel cell & gene therapy products
  • Partner Allogene (via Servier) is enrolling patients in the pivotal ALPHA3 trial for cema-cel with trial completion expected by year-end 2027
  • Partner Iovance is enrolling patients in a Phase 1/2 trial for IOV-4001 PD-1 inactivated TIL therapy for metastatic melanoma & mNSCLC
  • A conference call to discuss these results is scheduled for November 13 at 8 a.m. ET
Company
Cellectis Inc.
Keywords
Paris Stock Exchange:ALCLS, Cellectis Inc., earnings call, financial results, Q3 2026, in vivo, gene editing